EXEL
Exelixis, Inc. NASDAQ Listed Apr 17, 2000$46.22
Mkt Cap $11.7B
52w Low $33.76
78.6% of range
52w High $49.62
50d MA $43.39
200d MA $41.70
P/E (TTM)
15.2x
EV/EBITDA
12.5x
P/B
5.5x
Debt/Equity
0.1x
ROE
36.2%
P/FCF
14.0x
RSI (14)
—
ATR (14)
—
Beta
0.42
50d MA
$43.39
200d MA
$41.70
Avg Volume
2.8M
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
1851 Harbor Bay Parkway · Alameda, CA 94502 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | AMC | 0.75 | 0.87 | +16.0% | 44.42 | +7.3% | +9.6% | -5.1% | — | — | — | — |
| Feb 10, 2026 | AMC | 0.77 | 0.94 | +22.1% | 42.98 | +1.1% | -0.1% | -0.6% | +2.9% | +0.4% | +0.9% | — |
| Nov 4, 2025 | AMC | 0.69 | 0.78 | +13.9% | 37.90 | +5.5% | +6.5% | +1.1% | +0.0% | +1.5% | +3.8% | — |
| Jul 28, 2025 | AMC | 0.65 | 0.75 | +15.4% | 44.39 | -13.8% | -16.8% | -0.2% | -1.7% | +2.9% | -1.2% | — |
| May 13, 2025 | AMC | 0.36 | 0.62 | +73.1% | 36.95 | +10.0% | +20.8% | +3.6% | -1.9% | -1.6% | -0.7% | — |
| Feb 11, 2025 | AMC | 0.51 | 0.55 | +7.8% | 32.81 | +1.2% | -0.0% | +5.2% | +1.5% | -2.3% | +2.5% | — |
| Oct 29, 2024 | AMC | 0.35 | 0.40 | +14.3% | 28.73 | +9.3% | +12.9% | +2.3% | +2.8% | +0.5% | +1.4% | — |
| Aug 6, 2024 | AMC | 0.30 | 0.77 | +156.7% | 23.45 | +6.6% | +13.1% | +2.5% | -0.7% | -0.1% | -0.9% | — |
| Apr 30, 2024 | AMC | 0.28 | 0.17 | -39.3% | 23.46 | -7.8% | -6.5% | +0.9% | -1.0% | +0.0% | +1.1% | — |
| Feb 6, 2024 | AMC | 0.21 | 0.27 | +28.6% | 21.83 | -3.4% | -7.6% | -0.0% | +0.2% | +0.8% | -0.8% | — |
| Nov 1, 2023 | AMC | 0.10 | 0.10 | +0.0% | 21.02 | -2.6% | -4.2% | +4.3% | -0.8% | +1.3% | -1.8% | — |
| Aug 1, 2023 | AMC | 0.16 | 0.25 | +56.2% | 19.63 | +1.9% | +3.6% | +2.1% | -2.4% | -0.1% | +1.2% | — |
| May 9, 2023 | AMC | 0.15 | 0.12 | -20.0% | 19.23 | +0.0% | +0.8% | -0.2% | -0.9% | +1.7% | -1.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 20 | Barclays | Maintains | Equal Weight → Equal Weight | — | $44.89 | $44.99 | +0.2% | -2.9% | +5.2% | +2.1% | -1.7% | -2.4% |
| Mar 2 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $44.06 | $42.00 | -4.7% | -6.9% | -0.7% | +2.3% | -1.0% | +0.7% |
| Feb 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $42.94 | $42.83 | -0.3% | -0.6% | +2.9% | +0.4% | +0.9% | -0.7% |
| Feb 11 | Stifel | Maintains | Hold → Hold | — | $42.98 | $43.46 | +1.1% | -0.1% | -0.6% | +2.9% | +0.4% | +0.9% |
| Feb 11 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $42.98 | $43.46 | +1.1% | -0.1% | -0.6% | +2.9% | +0.4% | +0.9% |
| Feb 11 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $42.98 | $43.46 | +1.1% | -0.1% | -0.6% | +2.9% | +0.4% | +0.9% |
| Feb 4 | Barclays | Maintains | Equal Weight → Equal Weight | — | $42.59 | $42.79 | +0.5% | +0.1% | -0.7% | +3.6% | +0.1% | -2.2% |
| Feb 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $42.81 | $42.51 | -0.7% | -0.5% | +0.1% | -0.7% | +3.6% | +0.1% |
| Feb 2 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $41.36 | $42.01 | +1.6% | +3.5% | -0.5% | +0.1% | -0.7% | +3.6% |
| Jan 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $43.61 | $43.80 | +0.4% | +0.3% | -2.5% | -0.9% | -2.2% | +3.5% |
| Jan 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $46.19 | $45.37 | -1.8% | -4.4% | -0.2% | +0.0% | +0.0% | +2.6% |
| Jan 8 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $46.19 | $45.37 | -1.8% | -4.4% | -0.2% | +0.0% | +0.0% | +2.6% |
| Nov 6 | UBS | Maintains | Neutral → Neutral | — | $40.37 | $40.05 | -0.8% | +1.1% | +0.0% | +1.5% | +3.8% | +1.4% |
| Nov 5 | Barclays | Maintains | Equal Weight → Equal Weight | — | $37.90 | $40.00 | +5.5% | +6.5% | +1.1% | +0.0% | +1.5% | +3.8% |
| Nov 5 | TD Cowen | Maintains | Buy → Buy | — | $37.90 | $40.00 | +5.5% | +6.5% | +1.1% | +0.0% | +1.5% | +3.8% |
| Nov 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.90 | $40.00 | +5.5% | +6.5% | +1.1% | +0.0% | +1.5% | +3.8% |
| Nov 5 | Morgan Stanley | Maintains | Overweight → Overweight | — | $37.90 | $40.00 | +5.5% | +6.5% | +1.1% | +0.0% | +1.5% | +3.8% |
| Nov 3 | Guggenheim | Downgrade | Buy → Neutral | — | $38.67 | $37.55 | -2.9% | -1.6% | -0.4% | +6.5% | +1.1% | +0.0% |
| Oct 21 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $34.54 | $35.05 | +1.5% | +4.6% | -0.1% | +5.5% | +1.8% | +3.3% |
| Oct 21 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $34.54 | $35.05 | +1.5% | +4.6% | -0.1% | +5.5% | +1.8% | +3.3% |
| Oct 21 | Leerink Partners | Upgrade | Market Perform → Outperform | — | $34.54 | $35.05 | +1.5% | +4.6% | -0.1% | +5.5% | +1.8% | +3.3% |
| Oct 21 | Morgan Stanley | Maintains | Overweight → Overweight | — | $34.54 | $35.05 | +1.5% | +4.6% | -0.1% | +5.5% | +1.8% | +3.3% |
| Sep 17 | Morgan Stanley | Maintains | Overweight → Overweight | — | $39.14 | $39.66 | +1.3% | +3.3% | +0.0% | -0.9% | -1.3% | +0.6% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.41 | $37.52 | +0.3% | +1.4% | +1.4% | -0.1% | -0.4% | -1.4% |
| Jul 30 | UBS | Maintains | Neutral → Neutral | — | $36.94 | $37.14 | +0.5% | -0.2% | -1.7% | +2.9% | -1.2% | +1.8% |
| Jul 29 | Guggenheim | Maintains | Buy → Buy | — | $44.39 | $38.26 | -13.8% | -16.8% | -0.2% | -1.7% | +2.9% | -1.2% |
| Jul 29 | Truist | Maintains | Buy → Buy | — | $44.39 | $38.26 | -13.8% | -16.8% | -0.2% | -1.7% | +2.9% | -1.2% |
| Jul 29 | Stifel | Maintains | Hold → Hold | — | $44.39 | $38.26 | -13.8% | -16.8% | -0.2% | -1.7% | +2.9% | -1.2% |
| Jul 29 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $44.39 | $38.26 | -13.8% | -16.8% | -0.2% | -1.7% | +2.9% | -1.2% |
| Jul 29 | Morgan Stanley | Maintains | Overweight → Overweight | — | $44.39 | $38.26 | -13.8% | -16.8% | -0.2% | -1.7% | +2.9% | -1.2% |
| Jul 29 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $44.39 | $38.26 | -13.8% | -16.8% | -0.2% | -1.7% | +2.9% | -1.2% |
| Jul 22 | Morgan Stanley | Maintains | Overweight → Overweight | — | $44.26 | $44.29 | +0.1% | +0.5% | +2.1% | -1.3% | +1.8% | -2.7% |
| Jul 15 | Truist | Maintains | Buy → Buy | — | $45.58 | $45.59 | +0.0% | -3.3% | +1.7% | +0.1% | -0.9% | -0.5% |
| Jul 11 | UBS | Maintains | Neutral → Neutral | — | $45.17 | $45.00 | -0.4% | -0.7% | +1.6% | -3.3% | +1.7% | +0.1% |
| Jul 10 | Barclays | Maintains | Equal Weight → Equal Weight | — | $44.07 | $44.24 | +0.4% | +2.5% | -0.7% | +1.6% | -3.3% | +1.7% |
| Jul 8 | RBC Capital | Downgrade | Outperform → Sector Perform | — | $44.16 | $43.82 | -0.8% | -1.5% | +1.3% | +2.5% | -0.7% | +1.6% |
| Jun 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $43.67 | $43.87 | +0.5% | +0.9% | -1.0% | +1.6% | +4.2% | -4.3% |
| Jun 24 | Stephens & Co. | Upgrade | Equal Weight → Overweight | — | $43.37 | $44.55 | +2.7% | +5.4% | -4.8% | -1.0% | +1.3% | +0.9% |
| Jun 23 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $40.37 | $49.43 | +22.4% | +7.4% | +5.4% | -4.8% | -1.0% | +1.3% |
| Jun 23 | Truist | Maintains | Buy → Buy | — | $40.37 | $49.43 | +22.4% | +7.4% | +5.4% | -4.8% | -1.0% | +1.3% |
| Jun 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $41.43 | $41.59 | +0.4% | +0.8% | -0.5% | +0.4% | -0.9% | -1.5% |
| Jun 5 | BofA Securities | Maintains | Neutral → Neutral | — | $42.22 | $42.14 | -0.2% | +0.4% | +1.6% | -0.3% | -0.9% | -2.6% |
| May 15 | Citigroup | Maintains | Buy → Buy | — | $44.65 | $44.55 | -0.2% | +3.6% | -1.9% | -1.6% | -0.7% | -1.4% |
| May 14 | RBC Capital | Maintains | Outperform → Outperform | — | $36.95 | $40.65 | +10.0% | +20.8% | +3.6% | -1.9% | -1.6% | -0.7% |
| May 14 | Stifel | Maintains | Hold → Hold | — | $36.95 | $40.65 | +10.0% | +20.8% | +3.6% | -1.9% | -1.6% | -0.7% |
| May 14 | Morgan Stanley | Maintains | Overweight → Overweight | — | $36.95 | $40.65 | +10.0% | +20.8% | +3.6% | -1.9% | -1.6% | -0.7% |
| Apr 17 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $36.15 | $36.03 | -0.3% | +0.1% | -1.7% | +2.5% | +0.8% | +1.2% |
| Mar 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.01 | $37.25 | +0.6% | -0.5% | -0.4% | +0.6% | -1.4% | +1.8% |
| Mar 13 | RBC Capital | Maintains | Outperform → Outperform | — | $37.20 | $37.25 | +0.1% | -1.1% | -0.4% | +1.0% | -1.8% | +1.9% |
| Feb 24 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $36.85 | $36.39 | -1.2% | +0.8% | -0.6% | +1.7% | +0.3% | +2.8% |
No insider trades available.
8-K · 8.01
!! High
Exelixis, Inc. -- 8-K 8.01: Material Event / Announcement
Exelixis' board authorized a $750 million share repurchase program through December 2027, signaling management confidence in the company's valuation and returning capital to shareholders.
May 5
8-K
Exelixis Inc -- 8-K Filing
Exelixis appointed Hefti as Senior Vice President and General Counsel, strengthening its legal and executive leadership team.
Feb 10
Data updated apr 25, 2026 8:09am
· Source: massive.com